Integrating Theranostics Into Patient Care Pathways: AJR Expert Panel Narrative Review
出版年份 2022 全文链接
标题
Integrating Theranostics Into Patient Care Pathways: AJR Expert Panel Narrative Review
作者
关键词
-
出版物
AMERICAN JOURNAL OF ROENTGENOLOGY
Volume -, Issue -, Pages -
出版商
American Roentgen Ray Society
发表日期
2022-11-02
DOI
10.2214/ajr.22.28237
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Radiotheranostic Agents in Hematological Malignancies
- (2022) Jo Caers et al. Frontiers in Immunology
- Actinium-225 Prostate-specific Membrane Antigen Theranostics: Will α Beat β?
- (2021) Nattakorn Dhiantravan et al. EUROPEAN UROLOGY
- [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
- (2021) Michael S Hofman et al. LANCET
- PSMA Expression in Glioblastoma as a Basis for Theranostic Approaches: A Retrospective, Correlational Panel Study Including Immunohistochemistry, Clinical Parameters and PET Imaging
- (2021) Adrien Holzgreve et al. Frontiers in Oncology
- PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports
- (2021) M. J. M. Uijen et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Pitfalls and common findings in 68Ga-FAPI-PET – A pictorial analysis
- (2021) Lukas Kessler et al. JOURNAL OF NUCLEAR MEDICINE
- Overall survival results from the NETTER-1 trial in neuroendocrine tumours: an important milestone
- (2021) Irene Virgolini LANCET ONCOLOGY
- 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
- (2021) Jonathan R Strosberg et al. LANCET ONCOLOGY
- NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy
- (2020) Thomas A. Hope et al. JOURNAL OF NUCLEAR MEDICINE
- Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA
- (2020) Benedikt Feuerecker et al. EUROPEAN UROLOGY
- How We Do It: A Multidisciplinary Approach to 177Lu DOTATATE Peptide Receptor Radionuclide Therapy
- (2020) Brian J. Burkett et al. RADIOLOGY
- Peptide Receptor Radiotherapy: Current Approaches and Future Directions
- (2019) Grace Kong et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)
- (2019) Clemens Kratochwil et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer
- (2019) Jens Kurth et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- PTEN and Gynecological Cancers
- (2019) Camilla Nero et al. Cancers
- SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework
- (2018) Rudolf A. Werner et al. JOURNAL OF NUCLEAR MEDICINE
- Tumor lysis syndrome: a rare, but serious complication of radioligand therapies
- (2018) Kai Huang et al. JOURNAL OF NUCLEAR MEDICINE
- A systematic review and meta-analysis of gastrointestinal events associated with nonoperative therapies for neuroendocrine tumors
- (2018) Quhui Wu et al. OncoTargets and Therapy
- Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors
- (2017) Clément Morgat et al. JOURNAL OF NUCLEAR MEDICINE
- Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors
- (2017) Lucia Baratto et al. MOLECULAR IMAGING AND BIOLOGY
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- (2017) Jonathan Strosberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up
- (2016) Dieter Hörsch et al. EUROPEAN JOURNAL OF CANCER
- Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course
- (2015) Hendrik Bergsma et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Dual tracer imaging approach in assessing tumor biology and heterogeneity in neuroendocrine tumors: its correlation with tumor proliferation index and possible multifaceted implications for personalized clinical management decisions, with focus on PRRT
- (2014) Sandip Basu et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Gastrin-Releasing Peptide Receptor Expression in Lung Cancer
- (2013) Jane Mattei et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- In Vivo Imaging of Prostate Cancer Using [68Ga]-Labeled Bombesin Analog BAY86-7548
- (2013) E. Kahkonen et al. CLINICAL CANCER RESEARCH
- Radioactive iodine in the treatment of medullary thyroid carcinoma: a controlled multicenter study
- (2013) J A A Meijer et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
- (2013) A. Sabet et al. JOURNAL OF NUCLEAR MEDICINE
- Plasma Pharmacokinetics, Whole-Body Distribution, Metabolism, and Radiation Dosimetry of 68Ga Bombesin Antagonist BAY 86-7548 in Healthy Men
- (2013) A. Roivainen et al. JOURNAL OF NUCLEAR MEDICINE
- Profiling gastrin-releasing peptide receptor in prostate tissues: Clinical implications and molecular correlates
- (2011) Marc Beer et al. PROSTATE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started